Related references
Note: Only part of the references are listed.Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria
Gary J. Noel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure, infections
George H. Talbot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections
Scott T. Micek
CLINICAL INFECTIOUS DISEASES (2007)
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis, model
Cedric Jacqueline et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection
S. L. Davis et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Bactericidal activity and resistance development profiling of dalbavancin
Beth P. Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Anti-infectives - Investigational treatments for postoperative surgical site infections
Garyphallia Poulakou et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
High-level vancomycin-resistant staphylococcus aureus isolates associated with a polymicrobial biofilm
Linda M. Weigel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy
Karen Bush et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin
Diane M. Anastasiou et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Device-associated nosocomial infections in 55 intensive care units of 8 developing countries
Victor D. Rosenthal et al.
ANNALS OF INTERNAL MEDICINE (2006)
Clinical experience with recently approved antibiotics
David L. Paterson
CURRENT OPINION IN PHARMACOLOGY (2006)
De-escalation therapy in ventilator-associated pneumonia
Michael S. Niederman
CURRENT OPINION IN CRITICAL CARE (2006)
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
Vance G. Fowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dalbavancin: A novel lipoglycopeptide antibacterial
Scott D. Pope et al.
PHARMACOTHERAPY (2006)
Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy
Susanne M. Roberts et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Serotonin toxicity associated with the use of linezolid: A review of postmarketing data
KR Lawrence et al.
CLINICAL INFECTIOUS DISEASES (2006)
The future should not look like the past
[Anonymous]
LANCET INFECTIOUS DISEASES (2006)
Oritavancin - an investigational glycopeptide antibiotic
KE Ward et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models:: Identification of an in vivo pharmacokinetic-pharmacodynamic target
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria:: FAST 2 study
ME Stryjewski et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Community-acquired methicillin-resistant Staphylococcus aureus:: current perspectives
MFQ Kluytmans-VandenBergh et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
PC Appelbaum
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
LZ Cui et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Effect of dalbavancin on the normal intestinal microflora
Carl Erik Nord et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy
G Sakoulas et al.
CLINICAL INFECTIOUS DISEASES (2006)
Evaluation of PPI-0903M (T91825), a novel cephalosporin:: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests
RN Jones et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections
LE Jauregui et al.
CLINICAL INFECTIOUS DISEASES (2005)
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin
T Bogdanovich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam
EJ Ellis-Grosse et al.
CLINICAL INFECTIOUS DISEASES (2005)
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data
T Babinchak et al.
CLINICAL INFECTIOUS DISEASES (2005)
Tigecycline: A new glycylcycline for treatment of serious infections
GA Noskin
CLINICAL INFECTIOUS DISEASES (2005)
Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital
B Sancak et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia
JK Long et al.
MAYO CLINIC PROCEEDINGS (2005)
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains
HS Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Investigational new drugs for the treatment of resistant pneumococcal infections
HL Hoffman-Roberts et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Telavancin:: in vitro activity against staphylococci in a biofilm model
S Gander et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact
JA Silverman et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria
ME Stryjewski et al.
CLINICAL INFECTIOUS DISEASES (2005)
Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation
F Van Bambeke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Severe myopathy and possible hepatotoxicity related to daptomycin
K Echevarria et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo
RO Darouiche et al.
JOURNAL OF INFECTION (2005)
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
MB Dorr et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens
I Raad et al.
CLINICAL INFECTIOUS DISEASES (2005)
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide
G Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects
JP Shaw et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose
GJ Fetterly et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania
NC Clark et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria
A King et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers
A Leighton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid
AP Johnson et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates
L Deshpande et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Staphylococcus aureus with reduced susceptibility to vancomycin
SE Cosgrove et al.
CLINICAL INFECTIOUS DISEASES (2004)
Peripheral neuropathy associated with prolonged use of linezolid
AM Bressler et al.
LANCET INFECTIOUS DISEASES (2004)
Cellular pharmacokinetics and pharmaco dynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages
F Van Bambeke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Staphylococcus aureus:: superbug, super genome?
JA Lindsay et al.
TRENDS IN MICROBIOLOGY (2004)
Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center
B Bozdogan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Approaches to vancomycin-resistant enterococci
C Torres-Viera et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2004)
Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects
S Burriere et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model
KL LaPlante et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Glycopeptide antibiotics from conventional molecules to new derivatives
F Van Bambeke et al.
DRUGS (2004)
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections
TR Fritsche et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
RD Arbeit et al.
CLINICAL INFECTIOUS DISEASES (2004)
Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects
SM Bhavnani et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection
TS Naimi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center
B Bozdogan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci
LM Deshpande et al.
CLINICAL MICROBIOLOGY AND INFECTION (2003)
Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
JA Silverman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides
E Cercenado et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis
C Cabellos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection
CJ Boylan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects
BH Dvorchik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus
K Sieradzki et al.
JOURNAL OF BACTERIOLOGY (2003)
Mechanism of action of oritavancin and related glycopeptide antibiotics
NE Allen et al.
FEMS MICROBIOLOGY REVIEWS (2003)
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci
RN Jones et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Hematologic effects of linezolid: Summary of clinical experience
SL Gerson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Thrombocytopenia associated with linezolid therapy
K Attassi et al.
CLINICAL INFECTIOUS DISEASES (2002)
Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci
N Woodford
MICROBIAL DRUG RESISTANCE (2001)
In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci
S Noviello et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin
J Gerber et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model
ME Rupp et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
RD Gonzales et al.
LANCET (2001)
Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis
A Lefort et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model
JR Aeschlimann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50
LZ Cui et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci
B Al-Nawas et al.
INFECTION (2000)
In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study
ML Zeckel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
